ForPatients
by Roche

Fallopian Tube Neoplasms Ovarian Neoplasms Peritoneal Neoplasms Ovarian Cancer

An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT01932125 ML28446

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.

Hoffmann-La Roche
Sponsor

Phase

NCT01932125 ML28446
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
Female	>= 18 Years	No

© 2022 F. Hoffmann-La Roche Ltd